Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Evolutionary and Structural Insights about Potential SARS-CoV-2 Evasion of Nirmatrelvir
Kai S. Yang, Sunshine Z. Leeuwon, Shiqing Xu, et al.
Journal of Medicinal Chemistry (2022) Vol. 65, Iss. 13, pp. 8686-8698
Open Access | Times Cited: 92

Showing 1-25 of 92 citing articles:

Multiple pathways for SARS-CoV-2 resistance to nirmatrelvir
Sho Iketani, Hiroshi Mohri, Bruce Culbertson, et al.
Nature (2022) Vol. 613, Iss. 7944, pp. 558-564
Open Access | Times Cited: 295
Naturally Occurring Mutations of SARS-CoV-2 Main Protease Confer Drug Resistance to Nirmatrelvir
Yanmei Hu, Eric M. Lewandowski, Haozhou Tan, et al.
ACS Central Science (2023) Vol. 9, Iss. 8, pp. 1658-1669
Open Access | Times Cited: 197
Naturally occurring mutations of SARS-CoV-2 main protease confer drug resistance to nirmatrelvir
Yanmei Hu, Eric M. Lewandowski, Haozhou Tan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 73
Alkyne Derivatives of SARS-CoV-2 Main Protease Inhibitors Including Nirmatrelvir Inhibit by Reacting Covalently with the Nucleophilic Cysteine
Lennart Brewitz, Leo Dumjahn, Yilin Zhao, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 4, pp. 2663-2680
Open Access | Times Cited: 44
Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease
Yugendar R. Alugubelli, Jing Xiao, Kaustav Khatua, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 6495-6507
Open Access | Times Cited: 16
An orally bioavailable SARS-CoV-2 main protease inhibitor exhibits improved affinity and reduced sensitivity to mutations
Michael Westberg, Yichi Su, Xinzhi Zou, et al.
Science Translational Medicine (2024) Vol. 16, Iss. 738
Open Access | Times Cited: 12
Oral Antiviral Treatment for COVID-19: A Comprehensive Review on Nirmatrelvir/Ritonavir
Karolina Akinosoglou, Georgios Schinas, Charalambos Gogos
Viruses (2022) Vol. 14, Iss. 11, pp. 2540-2540
Open Access | Times Cited: 53
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals
Yugendar R. Alugubelli, Zhi Geng, Kai S. Yang, et al.
European Journal of Medicinal Chemistry (2022) Vol. 240, pp. 114596-114596
Open Access | Times Cited: 36
Adjusted green HPLC determination of nirmatrelvir and ritonavir in the new FDA approved co-packaged pharmaceutical dosage using supported computational calculations
Mohamed S. Imam, Afnan S. Batubara, Mohammed Gamal, et al.
Scientific Reports (2023) Vol. 13, Iss. 1
Open Access | Times Cited: 25
The impact of SARS-CoV-2 3CL protease mutations on nirmatrelvir inhibitory efficiency. Computational insights into potential resistance mechanisms
Carlos A. Ramos‐Guzmán, Milorad Andjelkovic, Kirill Zinovjev, et al.
Chemical Science (2023) Vol. 14, Iss. 10, pp. 2686-2697
Open Access | Times Cited: 21
Resistance mechanisms of SARS-CoV-2 3CLpro to the non-covalent inhibitor WU-04
Lijing Zhang, Xuping Xie, Hannan Luo, et al.
Cell Discovery (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Design, Synthesis, and Unprecedented Interactions of Covalent Dipeptide-Based Inhibitors of SARS-CoV-2 Main Protease and Its Variants Displaying Potent Antiviral Activity
Philipp Flury, Nadine Krüger, Katharina Sylvester, et al.
Journal of Medicinal Chemistry (2025)
Closed Access
Research Progress on the Structure and Function, Immune Escape Mechanism, Antiviral Drug Development Methods, and Clinical Use of SARS-CoV-2 Mpro
Jiayi Ren, Zhengfu Zhang, Yi Xia, et al.
Molecules (2025) Vol. 30, Iss. 2, pp. 351-351
Open Access
Predicting Antiviral Resistance Mutations in SARS-CoV-2 Main Protease with Computational and Experimental Screening
Vishnu Mini Sasi, Sven Ullrich, Jennifer Ton, et al.
Biochemistry (2022) Vol. 61, Iss. 22, pp. 2495-2505
Open Access | Times Cited: 33
A multi-pronged evaluation of aldehyde-based tripeptidyl main protease inhibitors as SARS-CoV-2 antivirals
Yuying Ma, Kai S. Yang, Zhi Geng, et al.
European Journal of Medicinal Chemistry (2022) Vol. 240, pp. 114570-114570
Open Access | Times Cited: 32
Viral proteases as therapeutic targets
Taťána Majerová, Jan Konvalinka
Molecular Aspects of Medicine (2022) Vol. 88, pp. 101159-101159
Open Access | Times Cited: 30
Therapeutic and diagnostic applications of nanoparticles in the management of COVID-19: a comprehensive overview
Omid Gholizadeh, Saman Yasamineh, Parya Amini, et al.
Virology Journal (2022) Vol. 19, Iss. 1
Open Access | Times Cited: 26
Exploring diverse reactive warheads for the design of SARS-CoV-2 main protease inhibitors
Bin Tan, M. Sacco, Haozhou Tan, et al.
European Journal of Medicinal Chemistry (2023) Vol. 259, pp. 115667-115667
Open Access | Times Cited: 18
A MERS-CoV antibody neutralizes a pre-emerging group 2c bat coronavirus
Longping V. Tse, Yixuan J. Hou, Elizabeth McFadden, et al.
Science Translational Medicine (2023) Vol. 15, Iss. 715
Open Access | Times Cited: 17
Molecular medicinal insights into scaffold hopping-based drug discovery success
Ayan Acharya, Mukul Yadav, Mithilesh Nagpure, et al.
Drug Discovery Today (2023) Vol. 29, Iss. 1, pp. 103845-103845
Closed Access | Times Cited: 17
Identification of novel antiviral drug candidates using an optimized SARS-CoV-2 phenotypic screening platform
Denisa Bojková, Philipp Reus, Leona Panosch, et al.
iScience (2023) Vol. 26, Iss. 2, pp. 105944-105944
Open Access | Times Cited: 14
Computer-aided drug design of novel nirmatrelvir analogs inhibiting main protease of Coronavirus SARS-CoV-2
Kateryna Lohachova, Anastasiia S . Sviatenko, Alexander Kyrychenko, et al.
Journal of Applied Pharmaceutical Science (2024)
Open Access | Times Cited: 5
Proline Analogues
Vladimir Kubyshkin, Marina Rubini
Chemical Reviews (2024) Vol. 124, Iss. 13, pp. 8130-8232
Closed Access | Times Cited: 5
Advances and challenges in using nirmatrelvir and its derivatives against SARS-CoV-2 infection
Wujun Chen, Bing Liang, Xiaolin Wu, et al.
Journal of Pharmaceutical Analysis (2022) Vol. 13, Iss. 3, pp. 255-261
Open Access | Times Cited: 22
Multi-ligand molecular docking, simulation, free energy calculations and wavelet analysis of the synergistic effects between natural compounds baicalein and cubebin for the inhibition of the main protease of SARS-CoV-2
Hong Li, Akari Komori, Mingdi Li, et al.
Journal of Molecular Liquids (2023) Vol. 374, pp. 121253-121253
Open Access | Times Cited: 13
Page 1 - Next Page

Scroll to top